Patent application number | Description | Published |
20090274648 | HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors having the general formula | 11-05-2009 |
20090274652 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 11-05-2009 |
20090274656 | HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors are disclosed having the general formula: | 11-05-2009 |
20090285773 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 11-19-2009 |
20090285774 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 11-19-2009 |
20090297472 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 12-03-2009 |
20090304626 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 12-10-2009 |
20100080770 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 04-01-2010 |
20100080771 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 04-01-2010 |
20100081700 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 04-01-2010 |
20100150866 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 06-17-2010 |
20100272674 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula (I) | 10-28-2010 |
20110086858 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 04-14-2011 |
20110311482 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors are disclosed having the general formula: | 12-22-2011 |
20120093766 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 04-19-2012 |
20120093767 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 04-19-2012 |
20120213729 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 08-23-2012 |
20120330019 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors are disclosed having the general formula: | 12-27-2012 |
20130078214 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 03-28-2013 |
20130095063 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 04-18-2013 |
20130095066 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 04-18-2013 |
20130115190 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula (I) | 05-09-2013 |
20130129671 | Tripeptides Incorporating Deuterium as Inhibitors of Hepatitis C Virus - Hepatitis C virus inhibitors having the general formula (I) | 05-23-2013 |
20130142754 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula (I) | 06-06-2013 |
20130203758 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 08-08-2013 |
20130267713 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors are disclosed having the general formula: | 10-10-2013 |
20140079664 | Tripeptides Incorporating Deuterium as Inhibitors of Hepatitis C Virus - Hepatitis C virus inhibitors having the general formula (I) | 03-20-2014 |
20140127156 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula (I) | 05-08-2014 |
20140134130 | FUSED BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C - Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: | 05-15-2014 |
20140135335 | SPIRO BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C - Compounds of Formula I, including pharmaceutically acceptable salts, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: | 05-15-2014 |
20140163231 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors are disclosed having the general formula: | 06-12-2014 |
20140294898 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 10-02-2014 |